User blogs
1. Medvedev Prevails In Shanghai: Can anyone stop this man? The Russian outclassed Alexander Zverev to take the title in Shanghai without dropping a set. Medvedev is on a nine-match winning streak, all of which have come in straight sets, and he has prevailed in 29 of his past 32 matches. The 23-year-old also has more match wins (59) than anyone else on Tour this year.
2. Pavic/Soares Come Alive In Shanghai: Mate Pavic and Bruno Soares hadn't reached a final in the first seven tournaments of their new partnership, but they found their footing and defeated Lukasz Kubot/Marcelo Melo to prevail in Shanghai without dropping a set. It's the fourth Masters 1000 title for Soares and the first for Pavic.
3. Zverev Turns His Season Around: The German produced his best result of the year in Shanghai, defeating Roger Federer in the quarter-finals for his first Top 10 win of the season and then scoring a dominant semi-final victory over Berrettini. His week puts him in seventh place in the ATP Race to London as he looks to defend his title at the season-ending Nitto ATP Finals, held 10-17 November at The O2 in London.
4. Double The Fun: Stefanos Tsitsipas enjoyed one of the best days of his young career on Friday. The reigning Next Gen ATP Finals champion defeated Novak Djokovic in the quarter-finals for his first win over a current World No. 1., then learned he had qualified for his maiden appearance at the Nitto ATP Finals. The sixth seed in Shanghai advanced to the semi-finals before falling to eventual champion Medvedev.
5. Youth Movement: Djokovic and Federer were a combined 13-0 in Rolex Shanghai Masters quarter-finals before Friday, but that was before the ATP Tour's youth movement took over. Tsitsipas (d. Djokovic), Zverev (d. Federer) and Matteo Berrettini (d. Thiem) all scored big upsets, while Medvedev continued his run by defeating Fabio Fognini in the quarter-finals. It marked the first time time in 20 years that all four semi-finalists at a Masters 1000 event were under the age of 24.
6. London Calling: Kubot/Melo's quarter-final win in Shanghai over Ivan Dodig/Filip Polasek ensured they will return to the Nitto ATP Finals this year. Their season includes a title in Winston-Salem (d. Monroe/Sandgren) and runner-up showings at four events, including Shanghai (l. to Pavic/Soares) and the BNP Paribas Open (l. to Mektic/Zeballos).
7. Pretty Please, Son: Federer's parents are not a regular fixture at his matches, but Robert and Lynette Federer both accompanied him to Shanghai this year. It was Lynette's third trip to the city, but Robert's first, and he was so enamoured that he already wants his son to put the eighth Masters 1000 event of the year on his schedule for 2020.
8. Rivalry Bingo: Dominic Thiem and Pablo Carreno Busta squared off for the first time at an ITF Futures event in Morocco in 2012. Their rivalry quickly progressed to the ATP Challenger Tour the following year and reached the ATP Tour in 2015 with a showdown in Gstaad. The Austrian won their latest battle in Shanghai to take a 6-0 lead in their FedEx ATP Head2Head rivalry, but it likely won't be the last time they meet.
9. On Top Of The World: Juan Sebastian Cabal and Robert Farah clinched the year-end No. 1 ATP Doubles Team Ranking for the first time as a result of their second-round win over John Isner and Sam Querrey. They became the second all-South American doubles team to accomplish the feat since the ATP Doubles Team Rankings began in 1984. Cabal/Farah have won five-tour level titles this year, including their first two Grand Slam titles Wimbledon (d. Mahut/Roger-Vasselin) and the US Open (d. Mektic/Zeballos).
10. Roger Returns, On Twitter: By his own admission, Federer is not the most prolific tweeter and will take breaks from social media for months at a time. But the Swiss brushed off his Twitter account to answer fan questions and even ask for recommendations on what to see in Shanghai. With his next two tournaments coming up this month in Basel and Paris, its shouldn’t be long before we see Federer back on social media again.
But despite the Raptors’ defending-champion status, they certainly don’t feel like big favourites to repeat.One obvious reason for this is the departure of 2019 Finals MVP Kawhi Leonard, but another major factor is the insane amount of parity across the NBA this season.
For the first time in seemingly forever there’s no clear-cut favourite to win it all. Instead, there’s a large swath of good-to-very good teams that look like they have a legitimate shot or are, perhaps, just one piece or one big break short of one.
As such, this season we’re going to tackle the power rankings a little differently than in years past. Instead of ranking each team 1-30, we’re going to divvy up groups of teams into tiers.So, before the ball tips and things get going for real, here’s the first edition of the NBA Tier List.Due to a mixture of raw star power, depth and experience, these five clubs are the cream of the crop heading into the season.
Star capital is apparent across the board here, with players like LeBron James, Anthony Davis, Kawhi Leonard and Paul George on the Los Angeles Lakers and Clippers, respectively, in addition to reigning league MVP Giannis Antetokounmpo on the Milwaukee Bucks, and Joel Embiid and Ben Simmons on the Philadelphia 76ers.
The Denver Nuggets’ wattage isn’t as obvious, but Nikola Jokic was, and should still remain, an MVP candidate, while Canadian Jamal Murray could take the next step and become an all-star this season.
All of these teams are expected to compete for the top spots of their respective conferences on the strength of their top-end talent, but they all also feature a fair amount of depth in terms of role players and specialists who can help them get over the top.
As mentioned before, there’s a lot of parity around the league this season, but for the time being these fives team like the far-too-early championship favourites.This is what was meant by a ton of good-to-very good teams.
These eight clubs could easily leap into the group above if things break right. But the reason they’re not there now is because they each come with key questions that could hold them back.
For example, there’s little denying the Raptors’ depth, but without Leonard — one of the three best players in the league — how legitimate are their championship aspirations even if Pascal Siakam takes another step forward?
Or in the case of the Golden State Warriors and Houston Rockets, their top talent is literally MVP calibre, but what about their overall depth? And for teams like the Utah Jazz or Brooklyn Nets, while it’s true adding players like Mike Conley and Kyrie Irving is a big boost, the jury is still out on whether it’ll be enough.All of these teams have questions that need to be answered before they can make a leap into the top tier.None of these 10 clubs are outright bad, per se, but it’s hard to see them pushing for anything beyond the final three playoff spots in their respective conferences.
The Sacramento Kings are a perfect example of this. They’re a team with depth and talent — see players like De’Aaron Fox and Buddy Hield — and look primed to make a leap back to relevancy. Unfortunately for them, the West is so deep that relevancy likely means scratching for a No. 7 or 8 seed.
And looking at an Eastern Conference example, the Orlando Magic are a well-coached team with intriguing talent that should only grow after a respectable five-game playoff exit to the Raptors. But what is the Magic’s realistic ceiling here? Can Nikola Vucevic make yet another leap and turn this Orlando side from a No. 6 seed into a top-three seed in the East?
All of these squads have talent. The problem is they either don’t have enough of it or they’re simply going to get gate-kept by clubs within the higher tiers.
Alupent (Orciprenaline Sulfate)
Orciprenaline powder is a bronchodilating agent. The bronchospasm associated with various pulmonary diseases – chronic bronchitis, pulmonary emphysema, bronchial asthma, silicosis, tuberculosis, sarcoidosis and carcinoma of the lung, has been successfully reversed by therapy with orciprenaline.
Orciprenaline has the following major characteristics: The action of orciprenaline is one of beta stimulation. Receptor sites in the bronchi and bronchioles are more sensitive to the drug than those in the heart and blood vessels, so that the ratio of bronchodilating to cardiovascular effects is favorable. Consequently, it is usually possible clinically to produce good bronchodilation at dosage levels which are unlikely to cause cardiovascular side effects.
The efficacy of the bronchodilator after both oral and inhalation administration has been demonstrated by pulmonary function studies (spirometry, and by measurements of airways resistance by body plethysmography).Rapid onset of action follows administration of orciprenaline inhalants, and the effect is usually noted immediately. Following oral administration, the effect is usually noted within 30 minutes.The peak effect of bronchodilator activity following orciprenaline generally occurs within 60 to 90 minutes, and this activity lasts for 3 to 6 hours.Orciprenaline taken orally potentiates the action of a bronchodilator inhalant administered 90 minutes later, whereas no additive effect occurs when the drugs are given in reverse order.
Patients have not developed tolerance to the drug during prolonged therapy.No toxic effects on the liver, kidneys or hematologic system have been reported in the long-term use of orciprenaline in man.Indications And Clinical Uses: Orciprenaline has been found useful in the following conditions: bronchial asthma, chronic bronchitis, pulmonary emphysema.Orciprenaline is also useful in sarcoidosis, silicosis, carcinoma of the lung and tuberculosis when bronchospasm contributes to the disability.
Patients with chronic airways obstructive disease require long-term therapy with bronchodilators as an essential part of overall management aimed at lowering airways resistance and facilitating bronchial drainage. Orciprenaline has been shown to fulfill the basic requirements of such continued therapy in that it is effective both orally and as an inhalant, has a rapid and prolonged action, and has a low incidence of side effects.
Inhalation Aerosol: The efficacy of orciprenaline administered as an aerosol has been demonstrated by increased flow rates (FEV1, MMFR, MEFR, MBC) decreased airways resistance (body plethysmography), and decreased functional residual capacity (body plethysmography).
In one study the effect of 4.5 mg of orciprenaline has been compared with the effect of 0.45 mg of isoproterenol each drug being given as an aerosol over a period of 8 minutes. Although the improvement in pulmonary function was consistently better with orciprenaline, 1 hour, 3 hours, and 6 hours following inhalation, changes in pulse rate and blood pressure were less pronounced with orciprenaline. This indicated a more favorable ratio of bronchodilating to cardiovascular effects for orciprenaline.
In another study, orciprenaline 2% solution, racemic epinephrine 2.25% and isoproterenol 1% were each administered as aerosols on separate days. The aerosols were administered by hand nebulizer for 30 minutes or until cardiovascular side effects appeared.
The immediate effect of orciprenaline on airways resistance in this study was similar to that produced by isoproterenol and by racemic epinephrine. However, the reduction in airways resistance after orciprenaline was significantly greater than that seen with isoproterenol in 30 minutes after inhalation, and after 90 minutes the effect of orciprenaline was superior to both isoproterenol and racemic epinephrine.
Whereas isoproterenol aerosol and epinephrine aerosol produced only transient reductions in the functional residual capacity of less than 30 minutes duration, the effect of orciprenaline on this parameter remained significant up to 90 minutes after inhalation.
Syrup: The efficacy of orciprenaline has been demonstrated by improvement of flow rates (FEV1, MMFR, MEFR) and airways resistance measurements (body plethysmography). Repeated measurements of pulmonary function made over a 4-hour period show that orciprenaline 20 mg orally gives a generally better result regarding duration of action and magnitude of response than placebo, 100 mg methoxyphenamine, 30 mg ephedrine by mouth, or 10 mg isoproterenol sublingually.
The effect of an inhalant bronchodilator may be potentiated by oral administration of 20 mg of orciprenaline 90 minutes prior to use of the inhalant. No additive effect occurs when the drugs are given in reverse order. The probable reason for this is that a bronchodilator delivered to the lungs via the vascular system (i.v. or oral medication) acts upon bronchioles whether or not they are occluded. Such an effect causes a wider distribution in the lungs of a subsequently given drug, and consequently the bronchodilation is more intense. Knowledge of this interaction is of value when instructing patients in the combined use of oral and inhalant forms of orciprenaline.
Orciprenaline may be given orally in dosages ranging from 60 to 120 mg daily. An effective clinical response in adults and children above 12 years can be achieved by 20 mg orciprenaline 3 times daily, and at this dosage side effects are not significantly different from those following placebo. Orciprenaline at a dosage of 20 mg 4 times daily is well tolerated and side effects are usually mild. Only at dosages of 100 mg daily and above, do palpitations and tremulousness become troublesome. If high doses of orciprenaline are necessary, it may be possible to eliminate the side effects whilst continuing the same total daily dose, by administering 10 mg single doses at more frequent intervals.
General: The low incidence of side effects together with effective bronchodilation make orciprenaline acceptable to patients with chronic bronchial asthma for continuous use either alone or concurrently with corticosteroids. Some of these patients may be controlled with orciprenaline as the sole medication, and it may be possible to avoid the use of steroid therapy. In a proportion of individuals who are already taking corticosteroids, it may be possible to withdraw this medication and continue with orciprenaline alone. However, caution should be observed in this regard as many patients, particularly those with severe bronchial asthma, can be managed satisfactorily only if steroids and bronchodilators are given together.
Prolonged studies have shown that patients with bronchitis and emphysema respond to continuous therapy with orciprenaline. The frequency and severity of acute attacks decrease, and patients experience relief of wheezing, chest congestion and shortness of breath. A close association is apparent between objective measurements of pulmonary function and the subjective response.
Contra-Indications: Known sensitivity to the drug or other sympathomimetic amines. The use of orciprenaline and other beta stimulators is generally considered to be contraindicated in patients with cardiac arrhythmias associated with tachycardia.Beta blocking agents, (e.g. propranolol) effectively antagonize the action of orciprenaline. Their concomitant use, except in the treatment of accidental overdosage, is therefore contraindicated.
The global market size of Tulobuterol hydrochloride is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024.
Global Tulobuterol Hydrochloride Market Report 2019 – Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Tulobuterol Hydrochloride industry. The key insights of the report:
1.The report provides key statistics on the market status of the Tulobuterol Hydrochloride manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
2.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.
3.The report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for key vendors.
4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5.The report estimates 2019-2024 market development trends of Tulobuterol Hydrochloride industry.
6.Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out
7.The report makes some important proposals for a new project of Tulobuterol Hydrochloride Industry before evaluating its feasibility.
There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.
For competitor segment, the report includes global key players of Tulobuterol Hydrochloride as well as some small players.
Raloxifene Hydrochloride Tablets
Raloxifene Hydrochloride Tablets, USP is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see Clinical Studies (14.4)].
The effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see Clinical Studies (14.4)]. Twenty-seven percent of the participants received drug for 5 years. The long-term effects and the recommended length of treatment are not known.
High risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (LCIS) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer ≥1.66% (based on the modified Gail model). Among the factors included in the modified Gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. Currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.
After an assessment of the risk of developing breast cancer, the decision regarding therapy with Raloxifene Hydrochloride Tablets, USP should be based upon an individual assessment of the benefits and risks.
Raloxifene Hydrochloride Tablets, USP does not eliminate the risk of
breast cancer. Patients should have breast exams and mammograms before
starting Raloxifene Hydrochloride Tablets, USP and should continue
regular breast exams and mammograms in keeping with good medical
practice after beginning treatment with Raloxifene Hydrochloride
Tablets, USP.
For either osteoporosis treatment or prevention, supplemental calcium
and/or vitamin D should be added to the diet if daily intake is
inadequate. Postmenopausal women require an average of 1500 mg/day of
elemental calcium. Total daily intake of calcium above 1500 mg has not
demonstrated additional bone benefits while daily intake above 2000 mg
has been associated with increased risk of adverse effects, including
hypercalcemia and kidney stones. The recommended intake of vitamin D is
400 to 800 IU daily. Patients at increased risk for vitamin D
insufficiency (e.g., over the age of 70 years, nursing home bound, or
chronically ill) may need additional vitamin D supplements. Patients
with gastrointestinal malabsorption syndromes may require higher doses
of vitamin D supplementation and measurement of 25-hydroxyvitamin D
should be considered.
In clinical trials, raloxifene-treated women had an increased risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism). Other venous thromboembolic events also could occur. A less serious event, superficial thrombophlebitis, also has been reported more frequently with raloxifene than with placebo. The greatest risk for deep vein thrombosis and pulmonary embolism occurs during the first 4 months of treatment, and the magnitude of risk appears to be similar to the reported risk associated with use of hormone therapy. Because immobilization increases the risk for venous thromboembolic events independent of therapy, raloxifene should be discontinued at least 72 hours prior to and during prolonged immobilization (e.g., post-surgical recovery, prolonged bed rest), and raloxifene therapy should be resumed only after the patient is fully ambulatory. In addition, women taking raloxifene should be advised to move about periodically during prolonged travel. The risk-benefit balance should be considered in women at risk of thromboembolic disease for other reasons, such as congestive heart failure, superficial thrombophlebitis, and active malignancy [see Contraindications (4.1) and Adverse Reactions (6.1)].
Raloxifene hydrochloride is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of raloxifene Hcl are largely mediated through binding to estrogen receptors.β-agonist Powder
This binding results in activation of estrogenic pathways in some tissues (agonism) and and the blockade of estrogenic pathways in other tissues (antagonism). The agonistic or antagonistic activity of raloxiffene depends on the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promotors.
Raloxifene Hcl appears to act as an estrogen agonist in bone. It decreases bone resorption and bone turnover, increases bone mineral density and decreases fracture incidence.
Raloxifene Hydrochloride Application:
1) Raloxifene Hcl used to prevent & treat osteoporosis in women who have undergone menopause.
2) Raloxifene Hcl used to decrease the risk of developing invasive breast cancer in women who are at high risk of developing this type of cancer or who have osteoporosis. Raloxifene Hcl cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition.
3) Raloxifene Hcl prevents and treats osteoporosis by mimicking the effects of estrogen to increase the density (thickness) of bone.
4) Raloxifene Hcl decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue, which may stop the development of tumors that need estrogen to grow.
High Purity Anastrozole Acetate Arimidex with Safety Shipping
Anastrozole powder
Alias: Arimidex
CAS No: 120511-73-1
MF: C17H19N5
MW: 293.37
Purity: 99%min
Appearance: White crystalline powder.
If you have any questions,welcome to your consult
Usage: An aromatase inhibitor. Used as an antineoplastic raw materials.
Potent selective triazole aromatase inhibitors, can inhibit the
cytochrome P-450 aromatase enzyme which depends blocking the
biosynthesis of estrogen, and estrogen to stimulate breast cancer cell
growth factors. Treatment of breast cancer, especially for those with
hormone relapse after adjuvant therapy after menopause for women with
advanced breast cancer.
Arimidex (anastrozoles) is the aromatase inhibitor of choice. Arimidex’s mechanism of action – blocking conversion of aromatizable steroids to estrogen – is in contrast to the mechanism of action of anti-estrogens such as clomiphene (Clomid) (Nolvadex), which block estrogen receptors in some tissues, and activate estrogen receptors in others.
Applications:
High Purity Anastrozoles/Arimidex/CAS No: 120511-73-1
The drug is appropriately used when using substantial amounts of
aromatizing steroids, or when one is prone to gynecomastia and using
moderate amounts of such steroids. Arimidex does not have the side
effects of aminoglutethimide (Cytadren) and can achieve a high degree of
estrogen blockade, much moreso than Cytadren. It is possible to reduce
estrogen too much with Arimidex, and for this reason blood tests, or
less preferably salivary tests, should be taken after the first week of
use to determine if the dosing is correct.
If refractory hypergranulation fails to respond to treatment with routine wound care and topical silver nitrate, we prescribe twice-daily application of timolol maleate ophthalmic gel forming solution 0.5% for up to 14 days or until complete resolution of the hypergranulation is achieved. We counsel patients to continue routine wound care with daily dressing changes in conjunction with topical timolol application.
We initiated treatment with topical timolol in a patient who developed hypergranulation at 2 separate electrodesiccation and curettage sites that was refractory to 6 weeks of routine wound care with white petrolatum under nonadherent sterile gauze dressings and 2 subsequent topical silver nitrate applications (Figure 1). After 2 weeks of treatment with topical timolol, resolution of the hypergranulation and re-epithelialization of the surgical sites was observed (Figure 2). Another patient presented with hypergranulation that developed following a traumatic injury on the left upper arm and had been treated unsuccessfully for several months at a wound care clinic with daily nonadherent sterile gauze dressings and both topical and oral antibiotics (Figure 3A). After treatment for 9 days with topical timolol, resolution of the hypergranulation and re-epithelialization of the surgical sites was observed (Figure 3B).
Beta-blockers are increasingly being used for management of chronic nonhealing wounds since the 1990s when oral administration of propranolol initially was reported to be an effective adjuvant therapy for managing severe burns.1 Since then, topical beta-blockers have been reported to be effective for management of ulcerated hemangiomas, venous stasis ulcers, chronic diabetic ulcers, and chronic nonhealing surgical wounds; however, there are no known reports of using topical beta-blockers for management of hypergranulation.2-5 We found timolol ophthalmic gel to be an excellent second-line therapy for management of postoperative hypergranulation if prior treatment with routine wound care and superpotent topical corticosteroids has failed. To date, we have found no reported adverse effects from the use of topical timolol for this indication that have required discontinuation of the medication. Use of this simple and safe intervention can be effective as a solution to a common postoperative condition.
Sensitive and fast analysis of terbutaline sulfate in food
Terbutaline
sulfate (TBS) is a β2-adrenoceptor agonist, overdoses of which can
cause serious harm and even be life-threatening to humans. Herein, we
demonstrate a simple and facile method for the preparation of a
molybdenum disulfide–gold nanoparticle composite (MoS2/AuNPs). The
obtained MoS2 and MoS2/AuNPs were characterized and investigated by
X-ray powder diffraction, scanning electron microscopy, and transmission
electron microscopy.
An MoS2/AuNPs-modified glassy carbon electrode (MoS2/AuNPs/GCE) was
constructed using the dropping method and used to study the
electrochemical behavior of TBS. The results indicated that the sensor
had excellent electrocatalytic activity for TBS, with detection
sensitivity for TBS more than 100 times higher compared with the bare
GCE. With the successive addition of TBS, the peak current of the
differential pulse stripping voltammogram (DPSV) of TBS was proportional
to its concentration within a certain range, with a linear range of
1–85 nmol L−1 and limit of detection (LOD) of up to 0.47 nmol L−1.
Furthermore, the modified electrode showed good stability,
reproducibility, and anti-interference ability, meaning that it could be
used to detect TBS in real samples.
Terbutaline sulfate 0.5 mg dry powder inhaler
(terbutaline sulfate)
This product is available as any of the above names but will be referred to as Bricanyl Turbohaler throughout this leaflet.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.β-agonist Powder
•
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet
1. What Bricanyl Turbohaler is and what it is used for
2. What you need to know before you use Bricanyl Turbohaler
3. How to use Bricanyl Turbohaler
4. Possible side effects
5. How to store Bricanyl Turbohaler
6. Contents of the pack and other information
1. WHAT BRICANYL TURBOHALER IS AND WHAT IT IS USED FOR
Bricanyl Turbohaler is an inhaler. It contains a medicine called terbutaline. This belongs to a group of medicines called ‘beta-agonists’. These work by relaxing certain muscles and opening up the airways in the lungs.
Bricanyl Turbohaler is used for asthma and other breathing problems where you have a tight chest and difficulty breathing.
2. WHAT YOU NEED TO KNOW BEFORE YOU USE BRICANYL TURBOHALER Do not use Bricanyl Turbohaler:
• If you are allergic to terbutaline.
Warnings and precautions
Talk to your doctor or pharmacist before using Bricanyl Turbohaler if:
• You have diabetes. If so, you may need some extra blood sugar tests when you start using Bricanyl Turbohaler.
• You have a history of heart disease, irregular heart rhythm or angina.
• You have an overactive thyroid gland.
If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before using Bricanyl
Turbohaler.
Other medicines and Bricanyl Turbohaler
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines that you buy without a prescription and herbal medicines. Bricanyl can affect the way that some medicines work and some medicines can have an effect on Bricanyl.In particular, tell your doctor or pharmacist if you are taking any of the following medicines:
• Steroid medicines (such as prednisolone).
• Medicines called ‘xanthines’ (such as theophylline).
• Medicines called ‘beta-blockers’ (such as atenolol or propranolol) including eye drops (such as timolol).
• Water tablets (diuretics) such as furosemide (also known as frusemide).
If you are to undergo surgery with general anaesthetics it is important that you inform your doctor about all medicines you use, including Bricanyl to protect you from adverse effects (e.g. irregular heart beat).Pregnancy, breast-feeding and fertility
• If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
• If you become pregnant while you are using Bricanyl Turbohaler, talk to your doctor straight away.Driving and using machines Bricanyl is not likely to affect you being able to drive or use any machines.
3. HOW TO USE BRICANYL TURBOHALER
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. If Bricanyl Turbohaler is to be used by a child, make sure that they use it correctly.
How much to take
• The recommended dose is one inhalation as required.
• Do not take more than four inhalations in any 24 hour period.
• One inhalation from your Bricanyl Turbohaler should last for up to six hours.
Talk to your doctor straight away if:
• Your breathing is getting worse.
• You often wake at night with asthma.
• You start getting a tight chest.
• You are not getting relief from your current dose.
These are signs that your asthma is not being controlled. You may need a different or additional treatment straight away.
Please read the complete instructions carefully before you start to take your medication Turbohaler is a multidose inhaler from which very small amounts of powder are
administered (Figure 1). When you breathe in through Turbohaler the powder is delivered to your lungs. It is therefore important that you inhale forcefully and deeply through the mouthpiece.
How to prepare a new Turbohaler for use Before using Turbohaler for the first time you need to prepare the inhaler for use.